文献速递消化系统肿瘤

PD-1/PD-L1与TIGIT/CD155空间定量分析预测胰腺腺鳞癌生存及辅助化疗耐药

Quantitative spatial profiling of PD-1/PD-L1 and TIGIT/CD155 interaction indicates poor survival outcome and resistance to adjuvant chemotherapy in pancreatic adenosquamous carcinoma.
PubMed 文献 · Eur J Cancer · 2025-11-29

本研究对120例胰腺腺鳞癌(PASC)治疗前肿瘤组织行多重定量免疫荧光,用AQUA算法空间分析PD-1/PD-L1与TIGIT/CD155共定位。高共定位评分是生存差的独立指标,低TIGIT/CD155共定位者更可能从辅助化疗(ACT)获益,结果在验证队列中可重复。

要点

  • PD-1/PD-L1与TIGIT/CD155高共定位提示PASC生存差。
  • 低TIGIT/CD155共定位评分者更可能从辅助化疗获益。
  • AQUA空间定量分析或可预测PASC预后与ACT反应。

核心结论

  • PD-1/PD-L1与TIGIT/CD155空间定量共定位评分可预测PASC生存结局和辅助化疗反应。

研究设计与样本

  • 回顾性分析120例PASC治疗前肿瘤组织,训练队列92例、验证队列28例,行多重定量免疫荧光及AQUA算法空间分析。

主要发现

  • 训练队列中PD-1/PD-L1共定位评分与晚期AJCC分期及神经周围侵犯显著相关。
  • 高PD-1/PD-L1与TIGIT/CD155共定位评分代表独特亚型,细胞毒性T细胞减少而抑制性免疫检查点分子升高。
  • 高PD-1/PD-L1与TIGIT/CD155共定位评分是生存结局更差的独立指标。
  • 低TIGIT/CD155共定位评分患者更可能从辅助化疗中获益。
  • 上述发现在外部验证队列中可重复。

临床怎么用

  • 对PASC治疗前标本行PD-1/PD-L1与TIGIT/CD155空间定量分析,辅助预后分层。
  • 低TIGIT/CD155共定位评分或可提示辅助化疗获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pancreatic adenosquamous carcinoma (PASC) is a rare, highly aggressive pancreatic cancer. Its therapeutic response varies, presumably due to tumor microenvironment (TME) complexity. METHODS: We investigated whether using multiparameter algorithms to measure key immunosuppressive mechanisms in the TME could identify strong predictors of survival and response to adjuvant chemotherapy (ACT). Pre-treatment tumor tissues from 120 patients with PASC were stained using multiplexed quantitative immunofluorescence (training cohort: 92 patients; validation cohort: 28 patients). Novel Automated Quantitative Analysis (AQUA) algorithms were used for spatial profiling of biomarker-positive cells. Biomarker co-localization was determined in pathologist-selected tumor regions. The impact of certain biomarker signatures, including TIGIT/CD155 co-expression and PD-1/PD-L1 interaction scores, on survival outcomes and response to ACT was determined. RESULTS: In the training cohort, PD-1/PD-L1 colocalization scores were significantly associated with advanced AJCC stage and perineural invasion. A TME with high PD-1/PD-L1 and TIGIT/CD155 co-localization scores represented a unique subtype, characterized by decreased cytotoxic T cell and increased suppressive immune checkpoint molecule levels. High PD-1/PD-L1 and TIGIT/CD155 co-localization scores were independent indicators of worse survival outcomes. Additionally, patients with low TIGIT/CD155 colocalization scores were more likely to benefit from ACT. These findings were reproducible in the external validation cohort. CONCLUSIONS: Quantitative spatial profiling of the PD-1/PD-L1 and TIGIT/CD155 suppression pathways using novel AQUA algorithms could help predict patient outcomes and ACT responses reliably, guiding development of more effective personalized management for PASC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chen X, Sun S, Li S, et al. Quantitative spatial profiling of PD-1/PD-L1 and TIGIT/CD155 interaction indicates poor survival outcome and resistance to adjuvant chemotherapy in pancreatic adenosquamous carcinoma. Eur J Cancer. 2025. PMID: 41337905. doi:10.1016/j.ejca.2025.116159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。